Controversy

PPARγ a target for treatment of colorectal cancer

Rajnish A. Gupta, Raymond N. DuBois

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Colorectal cancer (CRC) represents a significant cause of morbidity and mortality worldwide. Recently, ligands for the nuclear hormone receptor peroxisome proliferator-activated receptor γ (PPARγ) have exhibited promise in the treatment of CRC. For example, activation of PPARγ reduces the proliferation of cultured CRC cells grown in vitro or in vivo using the nude mouse xenograft model of tumor growth. Furthermore, agonists of the receptor also reduce the development of preneoplastic lesions in a model of carcinogen-induced CRC in rats. However, ligands for the receptor paradoxically enhance intestinal adenoma formation in another murine model of intestinal polyposis, the APCMin mice. These disparate results may be due to the inherent limitations of the APCMin mouse as a model for humans with CRC. Finally, genetic studies identifying loss of function mutations of PPARγ in human CRC specimens strongly suggest a tumor suppressive role for the receptor during the development of CRC.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Volume283
Issue number2 46-2
StatePublished - 2002
Externally publishedYes

Fingerprint

Peroxisome Proliferator-Activated Receptors
Colorectal Neoplasms
Intestinal Polyposis
Ligands
Cytoplasmic and Nuclear Receptors
Heterografts
Nude Mice
Carcinogens
Adenoma
Neoplasms
Morbidity
Mutation
Mortality
Growth

Keywords

  • Intestinal epithelial cell differentiation
  • Nuclear hormone receptor

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

Controversy : PPARγ a target for treatment of colorectal cancer. / Gupta, Rajnish A.; DuBois, Raymond N.

In: American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 283, No. 2 46-2, 2002.

Research output: Contribution to journalArticle

@article{5fa1856a523544a6951cc01ce59374f8,
title = "Controversy: PPARγ a target for treatment of colorectal cancer",
abstract = "Colorectal cancer (CRC) represents a significant cause of morbidity and mortality worldwide. Recently, ligands for the nuclear hormone receptor peroxisome proliferator-activated receptor γ (PPARγ) have exhibited promise in the treatment of CRC. For example, activation of PPARγ reduces the proliferation of cultured CRC cells grown in vitro or in vivo using the nude mouse xenograft model of tumor growth. Furthermore, agonists of the receptor also reduce the development of preneoplastic lesions in a model of carcinogen-induced CRC in rats. However, ligands for the receptor paradoxically enhance intestinal adenoma formation in another murine model of intestinal polyposis, the APCMin mice. These disparate results may be due to the inherent limitations of the APCMin mouse as a model for humans with CRC. Finally, genetic studies identifying loss of function mutations of PPARγ in human CRC specimens strongly suggest a tumor suppressive role for the receptor during the development of CRC.",
keywords = "Intestinal epithelial cell differentiation, Nuclear hormone receptor",
author = "Gupta, {Rajnish A.} and DuBois, {Raymond N.}",
year = "2002",
language = "English (US)",
volume = "283",
journal = "American Journal of Physiology - Endocrinology and Metabolism",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "2 46-2",

}

TY - JOUR

T1 - Controversy

T2 - PPARγ a target for treatment of colorectal cancer

AU - Gupta, Rajnish A.

AU - DuBois, Raymond N.

PY - 2002

Y1 - 2002

N2 - Colorectal cancer (CRC) represents a significant cause of morbidity and mortality worldwide. Recently, ligands for the nuclear hormone receptor peroxisome proliferator-activated receptor γ (PPARγ) have exhibited promise in the treatment of CRC. For example, activation of PPARγ reduces the proliferation of cultured CRC cells grown in vitro or in vivo using the nude mouse xenograft model of tumor growth. Furthermore, agonists of the receptor also reduce the development of preneoplastic lesions in a model of carcinogen-induced CRC in rats. However, ligands for the receptor paradoxically enhance intestinal adenoma formation in another murine model of intestinal polyposis, the APCMin mice. These disparate results may be due to the inherent limitations of the APCMin mouse as a model for humans with CRC. Finally, genetic studies identifying loss of function mutations of PPARγ in human CRC specimens strongly suggest a tumor suppressive role for the receptor during the development of CRC.

AB - Colorectal cancer (CRC) represents a significant cause of morbidity and mortality worldwide. Recently, ligands for the nuclear hormone receptor peroxisome proliferator-activated receptor γ (PPARγ) have exhibited promise in the treatment of CRC. For example, activation of PPARγ reduces the proliferation of cultured CRC cells grown in vitro or in vivo using the nude mouse xenograft model of tumor growth. Furthermore, agonists of the receptor also reduce the development of preneoplastic lesions in a model of carcinogen-induced CRC in rats. However, ligands for the receptor paradoxically enhance intestinal adenoma formation in another murine model of intestinal polyposis, the APCMin mice. These disparate results may be due to the inherent limitations of the APCMin mouse as a model for humans with CRC. Finally, genetic studies identifying loss of function mutations of PPARγ in human CRC specimens strongly suggest a tumor suppressive role for the receptor during the development of CRC.

KW - Intestinal epithelial cell differentiation

KW - Nuclear hormone receptor

UR - http://www.scopus.com/inward/record.url?scp=0036077277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036077277&partnerID=8YFLogxK

M3 - Article

VL - 283

JO - American Journal of Physiology - Endocrinology and Metabolism

JF - American Journal of Physiology - Endocrinology and Metabolism

SN - 0193-1849

IS - 2 46-2

ER -